Breakthrough at Texas A&M: A Nasal Spray Targets the Root of Brain Aging

In a development that could redefine how we approach age-related cognitive challenges, researchers at Texas A&M University have unveiled a promising nasal spray therapy. This innovation directly addresses neuroinflammaging, the chronic low-level inflammation in the brain's memory center that contributes to fog, forgetfulness, and heightened risk for conditions like Alzheimer's disease. By delivering tiny biological parcels called extracellular vesicles straight to the brain, the treatment has shown remarkable results in preclinical models, reducing inflammation, revitalizing cellular energy, and sharpening memory functions.

The hippocampus, crucial for forming new memories and adapting to change, often bears the brunt of this inflammatory process as we age. What was once viewed as an inevitable part of getting older now appears reversible with just two doses of this non-invasive spray. Led by Dr. Ashok Shetty, a distinguished professor and associate director at Texas A&M's Institute for Regenerative Medicine, the team has filed a U.S. patent, signaling strong potential for translation into human therapies.

This work not only highlights the cutting-edge research happening at Texas A&M's Naresh K. Vashisht College of Medicine but also underscores the university's role in tackling one of society's most pressing health issues. With dementia cases in the United States projected to climb toward 13 million by mid-century, such advancements offer hope for healthier aging across populations.

Understanding Neuroinflammaging: The Silent Driver of Cognitive Decline

Neuroinflammaging refers to a persistent, sterile inflammation primarily driven by overactive microglia, the brain's resident immune cells, in the hippocampus. Unlike acute inflammation that heals wounds, this slow-burning process generates oxidative stress, damages mitochondria—the cell's powerhouses—and disrupts memory consolidation. Over time, it leads to brain fog, slower learning, and vulnerability to neurodegenerative diseases.

Studies indicate that by age 65, subtle hippocampal changes affect daily recall and adaptability. In severe cases, it accelerates progression to Alzheimer's, where plaques and tangles compound the damage. Traditional anti-inflammatory drugs struggle to cross the blood-brain barrier, limiting their effectiveness. Texas A&M's approach flips this script by leveraging the nose-to-brain pathway, a natural route via olfactory nerves that circumvents barriers and targets inflammation at its source.

Dr. Shetty explains, "Brain age-related diseases like dementia are a major health concern worldwide. What we’re showing is brain aging can be reversed, to help people stay mentally sharp, socially engaged, and free from age-related decline." This perspective shifts the narrative from managing symptoms to restoring youthful brain dynamics.

The Innovators Behind the Spray: Texas A&M's Regenerative Medicine Pioneers

At the heart of this discovery is the Institute for Regenerative Medicine at Texas A&M University, a hub for stem cell and vesicle-based therapies. Dr. Ashok Shetty, with decades of expertise in hippocampal neurogenesis, leads the charge. His team, including senior research scientists Dr. Madhu Leelavathi Narayana and Dr. Maheedhar Kodali, engineered the spray using extracellular vesicles derived from human induced pluripotent stem cell-generated neural stem cells (hiPSC-NSC-EVs).

These vesicles, about 130 nanometers in size, naturally carry microRNAs—tiny gene regulators—that dial down inflammatory pathways without side effects. The collaborative effort pooled resources from the National Institute on Aging, enabling rigorous testing. "MicroRNAs act like master regulators," notes Dr. Narayana. "They help modulate many gene and signaling pathways in the brain."

This isn't Texas A&M's first foray into brain repair; prior work on stem cell grafts for epilepsy and stroke laid the groundwork. The institute's focus on scalable, non-invasive solutions positions it as a leader in translational neuroscience, benefiting students, faculty, and patients alike.

How the Nasal Spray Works: A Step-by-Step Breakdown

The therapy's elegance lies in its simplicity and precision. Here's how it unfolds:

• Step 1: Vesicle Preparation Neural stem cells, derived from human induced pluripotent stem cells, secrete extracellular vesicles loaded with anti-inflammatory microRNAs like miR-30e-3p and miR-181a-5p.
• Step 2: Intranasal Delivery Two doses, spaced two weeks apart, are administered via spray. Vesicles travel along olfactory nerves directly to the hippocampus, evading the blood-brain barrier.
• Step 3: Cellular Uptake Microglia absorb the vesicles; microRNAs suppress NLRP3 inflammasome and cGAS-STING pathways, halting cytokine storms (e.g., IL-1β, TNF-α).
• Step 4: Mitochondrial Revival Reduced oxidative stress reactivates neuronal mitochondria, boosting energy production via genes like Ndufs6 and Sdha.
• Step 5: Repair Activation Astrocyte hypertrophy shrinks, microglia shift to anti-inflammatory states, and neurogenesis pathways activate.
• Step 6: Cognitive Restoration Effects peak in weeks, lasting months, with improved object recognition and environmental adaptation.

"The mode of delivery is exciting," says Dr. Kodali. "Intranasal allows direct brain treatment without surgery." This mechanism offers advantages over oral drugs or injections, minimizing systemic exposure.

Study Design: Rigorous Testing in Preclinical Models

The research, published in the Journal of Extracellular Vesicles (DOI: 10.1002/jev2.70232), used late middle-aged (18-month-old) C57BL/6J mice—equivalent to 55-65-year-old humans. Both males and females received two intranasal doses of 12 billion EVs or vehicle control.

Assessments at 20.5 months included immunohistochemistry for inflammation markers (GFAP for astrocytes, IBA-1 for microglia), oxidative stress assays (MDA, PCs), mitochondrial gene expression (qRT-PCR), and behavioral tests like novel object recognition (NORT) and object location (OLT). Single-cell RNA sequencing profiled microglial transcriptomes seven days post-treatment.

Power analysis ensured statistical robustness; ANOVA and t-tests confirmed significance (p < 0.0001 for many outcomes). In vitro validation used RAW cells depleted of specific miRNAs, pinpointing miR-30e-3p for NLRP3 and miR-181a-5p for STING inhibition.

Photo by Chandler Cruttenden on Unsplash

Impressive Results: Quantifiable Gains in Brain Health

The outcomes were striking. Treated mice showed >50% reduction in microglial clusters (p < 0.0001) and astrocyte hypertrophy. Oxidative stress markers dropped (MDA by 40-60%, PCs similarly), while antioxidants like NRF2 and SOD rose 2-3 fold, especially in females.

Mitochondrial integrity improved: genes for respiratory chain complexes (Ndufs6/7, Sdha/b) upregulated 1.5-2x. Inflammatory proteins plummeted—NLRP3 components by 50-70%, p-cGAS/p-STING by 60%, IFN-α by 80%. scRNA-seq revealed 896 upregulated genes (oxidative phosphorylation enriched) and 2,025 downregulated (proinflammatory TLR/MAPK/TNF pathways).

Cognitively, discrimination indices in NORT/OLT surged 30-50% (p < 0.001), indicating sharper memory. Effects persisted months post-treatment, uniform across sexes. For full details, see the Texas A&M press release.

Potential to Combat Alzheimer's and Broader Dementia Crisis

With over 7 million Americans living with Alzheimer's today—projected to nearly double by 2060 per the Alzheimer's Association—therapies targeting early neuroinflammaging could delay onset by years. This spray's ability to recharge mitochondria and curb sterile inflammation positions it as a preventive for mild cognitive impairment transitioning to dementia.

Unlike plaque-clearing drugs like lecanemab, which require infusions and have side effects, this is non-invasive and addresses upstream causes. Dr. Shetty envisions it complementing lifestyle interventions, potentially enabling "successful brain aging"—staying sharp into the 80s and beyond.

Texas A&M's Role in Advancing Regenerative Neuroscience

The Institute for Regenerative Medicine exemplifies Texas A&M's commitment to high-impact brain research. Faculty like Dr. Shetty bridge basic science and clinical translation, training PhD students in EV engineering and hippocampal biology. This study involved interdisciplinary collaboration with veterinary biosciences for sequencing.

In higher education, such breakthroughs attract top talent, secure NIH funding (NIA-backed here), and foster spinouts. Texas A&M's patent filing could spawn startups, echoing successes in stem cell therapies for epilepsy. For aspiring researchers, explore research positions at leading US universities driving these innovations.

Comparisons to Existing Therapies and Emerging Alternatives

Other nasal sprays, like insulin formulations for Alzheimer's, show modest memory gains but lack this therapy's multi-pathway targeting. Stem cell EVs for TBI (earlier Texas A&M work) reduced inflammation similarly, but for aging, this is novel. Compared to anti-amyloid antibodies (e.g., donanemab), it's safer, cheaper, and upstream-focused.

• Benefits over infusions: No ARIA risk, outpatient-friendly.
• Vs. lifestyle alone: Faster, measurable cellular repair.
• Future combos: Pair with exercise or diet for synergy.

Limitations: Preclinical only; human trials needed for dosing/safety. Yet, EVs' biocompatibility bodes well.

Challenges Ahead and Optimistic Outlook

Scaling production of clinical-grade hiPSC-NSC-EVs requires GMP facilities, a focus at Texas A&M. Regulatory hurdles for novel biologics demand Phase I safety data, but intranasal precedents (e.g., esketamine) smooth the path. Equity concerns: Ensure access beyond elites, aligning with public health goals.

Dr. Shetty: "We’re aiming for successful brain aging: keeping people engaged, alert, and connected." With dementia's $360 billion annual US cost, this could save billions while enhancing quality of life. Watch for trials; meanwhile, prioritize sleep, exercise, and Mediterranean diets to combat inflammaging.

Photo by Laine Cooper on Unsplash

Stakeholder Perspectives and Broader Implications

Neurologists praise the multi-target approach: "Hits inflammation where drugs fail," per one expert. Patients' advocates highlight non-invasiveness for elderly. In academia, it boosts regenerative med programs; Texas A&M's model inspires peer institutions.

For higher ed, funding such work sustains grants, jobs. Explore research faculty roles in neuroscience. Ultimately, this Texas A&M gem promises a future where brain aging is managed proactively, empowering generations.